LIMERICK, Pa.--(BUSINESS WIRE)--Jun. 6, 2013--
Teleflex Incorporated (NYSE: TFX), a leading global provider of medical
devices for critical care and surgery, today announced the acquisition
of Eon Surgical, Ltd., a late stage development company that has
advanced a minimally invasive microlaparoscopy surgical platform
technology designed to enhance surgeons’ ability to perform scarless
surgery while producing better patient outcomes.
Microlaparoscopy, unlike NOTES (Natural OrificeTranslumenal Endoscopic
Surgery™) or single incision surgery, provides surgeons a mechanism for
performing minimally invasive procedures without significant changes in
technique. The technology has the ability to be utilized for an entire
procedure or as an adjunct to existing approaches that require
additional access without adding to larger incisions and the associated
risks.
While there are current technologies being marketed for use in
microlaparoscopy or needlescopic approaches, adoption has not been
significant due to limitations of available devices. The purchase of Eon
Surgical, coupled with already acquired intellectual property by
Teleflex, is targeted at removing barriers to broad market adoption.
“This acquisition is consistent with our focus on innovative
technologies and will greatly expand Teleflex’s offerings that address
the significant market opportunity for minimally invasive laparoscopic
procedures,” said Benson Smith, Chairman, President and CEO.
Commenting on the acquisition, Danny Farin, CEO and co-founder of Eon
Surgical, stated, "We are proud to be associated with a prestigious
industry partner like Teleflex. This is a wonderful opportunity to
accelerate the global expansion of our innovative platform, while
providing the highest level of support to surgeons throughout the world.
I am very thankful for the opportunity to work with Eon's synergistic,
highly skillful and professional team."
David Zigdon, CEO of RAD BioMed, Eon Surgical’s accelerator, added, "Eon
Surgical achieved extraordinary results in a remarkably short period of
time due to diligent and inspiring work that brought a novel concept
from inception to market in three years. Co-founders Danny Farin and
Shaul Shohat, together with Eon Surgical’s VP R&D, Yehuda Bachar, are to
be commended for accelerating the development of the technology at the
highest executional and strategic level."
The financial terms of the acquisition were not disclosed.
About Teleflex Incorporated
Teleflex is a leading global provider of specialty medical devices for a
range of procedures in critical care and surgery. Our mission is to
provide solutions that enable healthcare providers to improve outcomes
and enhance patient and provider safety. Headquartered in Limerick, PA,
Teleflex employs approximately 11,700 people worldwide and serves
healthcare providers in more than 140 countries. For additional
information about Teleflex please refer to www.teleflex.com.
About Eon Surgical Ltd.- EON Surgical, an Israeli company, was
founded under the auspices of the Rad BioMed Accelerator in May 2010,
with the vision to become a leading provider of solutions for
next-generation scarless surgery.
About RAD BioMed Accelerator Ltd. - RAD BioMed is a
success-accelerator for Israeli biomedical startups, and is part of the
RAD Group, one of Israel's most accomplished startup-to-successful-exit
generators. RAD BioMed's co-founders, Mr. Yehuda Zisapel and Prof. Nava
Zisapel, also co-founded Neurim Ltd., a leading Israeli biopharma
company which developed Circadin®, an approved and globally-marketed
treatment for sleep disorders. Based in Tel-Aviv, RAD BioMed minimizes
early-stage operational costs by providing access to state-of-the-art
facilities and laboratories, and is differentiated by the long-term
partnership it offers with a strategic umbrella of professional support
and services as well as financial backing and networking support for
follow-on activities.
Forward-Looking Statements
Any statements contained in this press release that do not describe
historical facts may constitute forward-looking statements. Any
forward-looking statements contained herein are based on our
management's current beliefs and expectations, but are subject to a
number of risks, uncertainties and changes in circumstances, which may
cause actual results or company actions to differ materially from what
is expressed or implied by these statements. These risks and
uncertainties are identified and described in more detail in our filings
with the Securities and Exchange Commission, including our Annual Report
on Form 10-K.
Source: Teleflex Incorporated
Teleflex Incorporated
Jake Elguicze
Treasurer and Vice
President, Investor Relations
610-948-2836